Pharmaceuticals

Drug Development Drug Pricing Weight Loss Drugs Drug Approval Drug Safety Prescription Drugs Clinical Trials Drug Manufacturing Diabetes Treatment Vaccines

Pfizer–Trump Drug-Pricing Deal and ‘TrumpRx’ Plan Jolt Health-Care Stocks Higher

The agreement links Medicaid price cuts to a three-year tariff reprieve for Pfizer, signaling clearer policy direction.

Pfizer Seen as Dividend Standout as It Strikes $4.9 Billion Metsera Deal

Galapagos Nears Decision on Cell Therapy Unit After Limited Offers Received

WHO Says Antibiotic Pipeline Is Thinning as Innovation Stalls

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

PharmaVoice and Healthcare Dive Publish 2026 Conference Calendars

Crinetics Wins FDA Approval for Oral Acromegaly Drug Palsonify as JMP Lifts Price Target

Merck Wins FDA Approval for Subcutaneous Keytruda as EU Panel Backs Infant RSV Preventive

Deals Set $40 Generics of Twice-Yearly HIV Prevention Shot for 120 Countries by 2027

Fluoxetine Rewires Prefrontal Interneurons’ Gene Programs, Easing Circuit Constraints

Jayson Tatum Backs Non-Opioid Pain Drug Journavx as He Details Achilles Rehab

HHS and FDA Open Review of Mifepristone’s Safety and Dispensing

Pfizer Lifts 2025 EPS Outlook, Targets $7.7 Billion in Savings as Dividend Draws Interest

Yahoo Finance Flags One Pharma Dividend Buy as Sector Slumps

Semnur Goes Public via Denali SPAC, Unveils $100 Million Bitcoin Stock Sale Plan

EU Panel Backs Tezspire for Chronic Rhinosinusitis With Nasal Polyps

White House Weighs Government Drug Portal Letting Patients Buy Direct From Manufacturers

AbbVie Extends Rinvoq U.S. Exclusivity to 2037 as AI Biotechs Move From Models to Medicines

FDA Grants Accelerated Approval to Forzinity, First Therapy for Barth Syndrome

Trump’s 1,000% Drug Price Claim Draws Ridicule After Fox Interview